Back to News
Market Impact: 0.2
Edwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives
Source: seekingalpha.com
Analyst InsightsHealthcare & BiotechCompany FundamentalsRegulation & Legislation
The analyst initiated coverage of Edwards Lifesciences with a Buy rating, citing recent FDA approvals, its niche cardiology portfolio, strong operating margins and operating cash flow. The positive fundamental view is tempered by EW’s price-return weakness versus key benchmarks this year.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
EW0.45
More News
- Analysts react as Binance freezes assets after $6.3 billion security breach
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- PC chip plunge wipes out a quarter of Intel’s value
- Intel plunges on a major guidance miss. What went wrong — and how to proceed